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Abstract The phosphorylation status of amyloid precursor pro-
tein (APP) at Thr668 is suggested to play a critical role in the
proteolytic cleavage of APP, which generates either soluble
APPL (sAPPL) and L-amyloid peptide (AL), the major compo-
nent of senile plaques in patient brains in£icted with Alzheimer’s
disease (AD), or soluble APPK (sAPPK) and a peptide smaller
than AL. One of the protein kinases known to phosphorylate
APPThr668 is cyclin-dependent kinase 5 (Cdk5). Cdk5 is acti-
vated by the association with its regulatory partner p35 or its
truncated form, p25, which is elevated in AD brains. The com-
parative e¡ects of p35 and p25 on APPThr668 phosphorylation
and APP processing, however, have not been reported. In this
study, we investigated APPThr668 phosphorylation and APP pro-
cessing mediated by p35/Cdk5 and p25/Cdk5 in the human neu-
roblastoma cell line SH-SY5Y. Transient overexpression of p35
and p25 elicited distinct patterns of APPThr668 phosphorylation,
speci¢cally, p35 increasing the phosphorylation of both mature
and immature APP, whereas p25 primarily elevated the phos-
phorylation of immature APP. Despite these di¡erential e¡ects
on APP phosphorylation, both p35 and p25 overexpression en-
hanced the secretion of AL, sAPPL, as well as sAPPK. These
results con¢rm the involvement of Cdk5 in APP processing, and
suggest that p35- and p25-mediated Cdk5 activities lead to dis-
crete APP phosphorylation.
4 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
The progressive extracellular accumulation of the 4-kDa
amyloid L-peptide (AL, senile plaques) in the central nervous
system is one of the characteristics of Alzheimer’s disease
(AD) pathology [1,2]. Senile plaques are predominantly com-
posed of AL peptides of 40^42 amino acids derived from
amyloid precursor protein (APP) [3] via proteolytic cleavage
by L- and Q-secretase [4]. APP is a type one transmembrane
glycoprotein that is ubiquitously expressed in mammalian tis-
sues [5]. There are three major isoforms of APP (APP695,
APP751, and APP770), consisting of 695, 751, and 770 amino
acids, respectively [5]. In addition to the generation of AL, the
cleavage of APP by L- and Q-secretases also gives rise to a
soluble N-terminal fragment, sAPPL. Alternatively, APP is
cleaved by K-secretase within the AL sequence resulting in
sAPPK, thus precluding the formation of AL [6,7].
In neuronal cells, APP695 is phosphorylated at multiple ser-
ine and threonine residues [8]. The phosphorylation of Thr668
conveys the most pronounced conformational change in the
APP cytoplasmic tail [9], and has been suggested to play im-
portant roles in neurite outgrowth [10], APP subcellular local-
ization [11], and APP processing [12]. Several protein kinases
are able to phosphorylate APPThr668 in vitro or in vivo [11^
14], but the cyclin-dependent kinase 5 (Cdk5) is the key kinase
responsible for the APPThr668 phosphorylation in neuronal
cells [11]. Cdk5 is a unique member of the small serine/threo-
nine kinase (Cdk) family [15] that plays a critical role in the
development of the central nervous system [16]. p35 is the
regulatory subunit of Cdk5. The binding of Cdk5 and p35
in neurons triggers Cdk5 enzymatic activity [17]. p35 contains
an amino-terminal myristoylation signal motif that anchors
the p35/Cdk5 complex to the cell membrane [15]. Therefore,
p35 dictates the substrate speci¢cities of Cdk5. p35 is known
to be proteolysed to form p25 by Ca2þ-dependent protease
calpain under neurotoxic conditions [18]. Unlike p35, p25
lacks the amino-terminal myristoylation signal motif. There-
fore, p25 is mainly distributed in the cytoplasm. Because p25
is more stable than p35, the accumulation of p25 in cells
causes constant association of p25 with Cdk5, which allows
the prolonged activation of Cdk5 [19] and the hyperphosphor-
ylation of cellular proteins such as Tau [20]. In this study, we
examined the speci¢c e¡ect of p35 and p25 on APPThr668
phosphorylation in neuroblastoma SH-SY5Y and a non-neu-
ronal cell line, HEK293, and we explored the e¡ect of p35 and
p25 on APP processing.
2. Materials and methods
2.1. Antibodies and reagents
Anti-p35/p25 and Cdk5 antibodies were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Anti-AL precursor protein
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polyclonal antibody (pAb) (CT695) was from Zymed Laboratories
(South San Francisco, CA, USA). Anti-APP monoclonal antibody
(mAb) 6E10 was obtained from Signet (Dedham, MA, USA), the
anti-sAPPL pAb was provided by Mr. E. Johnstone/Dr. S. Little
(Eli Lilly and Co), and the anti-phospho-APP (Thr668) antibody
was from Cell Signaling (Beverly, MA, USA). The Cdk5, p35, and
p25 cDNA constructs were kind gifts from Dr. L. H. Tsai (Harvard
Medical School, Boston, MA, USA), while the APP695 construct was
provided by Mr. E. Johnstone/Dr. S. Little. The transfection reagent
FuGENE6 was purchased from Roche (Indianapolis, IN, USA). The
protein molecular weight marker (Precision Protein Standards) was
from Bio-Rad. All other common reagents and cell culture media
were from Invitrogen Life Technologies (Carlsbad, CA, USA) unless
speci¢ed otherwise.
2.2. Cell culture
Human neuroblastoma SH-SY5Y cells were purchased from ATCC
(Manassas, VA, USA) and grown in minimum essential medium Ea-
gle/F-12K (1:1 mixture) containing 10% fetal bovine serum (FBS) and
1% penicillin^streptomycin. Human embryonic kidney (HEK293) cells
stably transfected with APP751 [21] were cultured in Dulbecco’s modi-
¢ed Eagle’s medium-F12 supplemented with 5% FBS, 20 mM HEPES,
300 Wg/ml G418 and 1% penicillin^streptomycin. All cell lines were
propagated in T75 £asks and subsequently plated in 24-well plates for
treatments. Cells were maintained at 37‡C in a humidi¢ed incubator
supplied with 5% CO2.
2.3. Transient transfection
Cells were seeded in 24-well plates and grown to reach 50^60%
con£uence at the time of transfection. Plasmid DNAs were ¢rst mixed
with FuGENE6 at the ratio of 1 Wg:3 Wl (DNA:FuGENE6) per 100 Wl
of OPTI-MEM (each well received 0.25 Wg DNA). The transfection
mixtures were incubated at room temperature for 30 min prior to the
addition to the cells. Cells were incubated with DNA mixture for the
entire duration of transfection (12^24 h).
2.4. Generation of SH-SY5Y cell line constitutively expressing
swAPP695
SH-SY5Y cells were transfected with a cDNA encoding APP751
bearing the Swedish mutation (swAPP695) using Lipofectamine Plus
(Invitrogen) according to the manufacturer’s instructions. Single cell
clones were generated by selection with 250 Wg/ml of G418.
2.5. Electrophoresis and Western immunoblotting
The NuPAGE Bis-Tris System (Invitrogen Life Technologies) was
utilized for electrophoresis and Western transfer. For the detection of
cell-associated proteins, cells were grown, treated in 24-well plates,
and lysed with 200 Wl and 400 Wl of LDS sample bu¡er for SH-
SY5Y and HEK293 cells, respectively. For the detection of APPs
released into media, conditioned media were collected, centrifuged
at 14 000 rpm for 10 min (4‡C) to remove cell debris, and then mixed
with LDS sample bu¡er. Cell lysates or conditioned media were sep-
arated on 10% Bis-Tris gels (200 V, 1 h), and transferred to nitro-
cellulose membranes (0.2 Wm; 50 V, 2 h), followed by Western im-
munoblotting analyses as described previously [22]
2.6. Measurement of AL peptides in culture media
The secreted total AL and AL142 peptides in conditioned media
were measured using a sandwich enzyme-linked immunosorbent assay
(ELISA) as previously described [22]. In essence, a⁄nity-puri¢ed mAb
266.2 (1.5 Wg/well) was applied as the capture antibody for total AL,
mAb 21F12 (0.5 Wg/well) was used as capture antibody for AL142 and
biotinylated mAb 3D6 was used as detection antibody. Streptavidin^
horseradish peroxidase was purchased from Amersham and TMB
Substrate Kit was from Pierce. All assays were performed in 96-well
Immulon 4 microtiter plates (Dynex Technologies, Chantilly, VA,
USA).
2.7. Statistics
Statistical analysis was performed using the paired t-test. Data are
presented as meanTS.E.M., P6 0.05 was considered signi¢cant.
3. Results and discussion
3.1. p35/Cdk5 and p25/Cdk5 di¡erentially phosphorylate APP
Previous studies from several groups have shown that the
phosphorylation of APP at Thr668 is important for certain
biological/pathological processes [10]. It has been demon-
strated that Cdk5, when activated by its regulating partner
p35, directly phosphorylates APPThr668 [11]. p25, the proteo-
lytic product of p35, has been reported to possess the full
functionality of p35 [15]. However, the properties of p25 in
catalyzing APP phosphorylation have not been characterized.
Because p25, but not p35, has recently been proposed to play
an important role in AD pathogenesis, it is of great interest to
evaluate the characteristics of p35 and p25 in mediating APP
phosphorylation. To that end, we transiently co-expressed p35
or p25 with APP695 in neuroblastoma SH-SY5Y and eval-
uated APP phosphorylation by Western analyses using an
antibody speci¢cally recognizing the Cdk5 phosphorylation
site ^ Thr668 on APP [12]. Fig. 1A demonstrates that p35
stimulated the phosphorylation of both mature APP
(mAPP: N- and O-glycosylated, tyrosyl-sulfated) and imma-
ture APP (imAPP, N-glycosylated only), whereas p25 primar-
ily increases the phosphorylation of imAPP (upper panel).
The total APP expression levels were not increased by p35
or p25 transfection (lower panel). Fig. 1B shows the compa-
rable and abundant overexpression of p35 and p25 in SH-
Fig. 1. Overexpression of p35 and p25 distinctly increases APP
phosphorylation in SH-SY5Y neuroblastoma cells. A: SH-SY5Y
cells were transiently transfected with APP695 alone (lane 1), co-
transfected with p35 and APP695 (lane 2), or co-transfected with p25
and APP695 (lane 3). Twenty-four hours following transfection, cells
were directly lysed in LDS sample bu¡er and cell lysates were sub-
jected to Western blotting. The phosphorylated APPThr668 was de-
tected by anti-phospho-APP (Thr668) antibody (top blot), while the
total APP was probed with CT695 (bottom blot). B: Protein levels
of p35 and p25 in the cell preparations described in A, as detected
by antibody C-19, which recognizes both p35 and p25. Data are
representative of two experiments.
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SY5Y cells after transfection. These data suggest similar ca-
pabilities of p25 and p35 in regulating Cdk5 catalytic activities
with preferential substrate selection: p35/Cdk5 targeting both
mature and immature APP while p25/Cdk5 prefers the imma-
ture form of APP.
To substantiate the observation of the di¡erential e¡ects of
p35/Cdk5 and p25/Cdk5 on the phosphorylation of imAPP
and mAPP in SH-SY5Y cells, we extended our study to in-
vestigate the phosphorylation of mAPP and imAPP by p35/
Cdk5 and p25/Cdk5 in HEK293 cells constitutively overex-
pressing APP751 (Fig. 2A) or swAPP751 (Fig. 2B), two well
established cell systems for studies of APP processing [23^
25]. Because these cells express low levels of endogenous
Cdk5, cotransfections of p35 and Cdk5 or p25 and Cdk5
were performed. Expressions of p35/Cdk5 and p25/Cdk5 did
not alter the protein levels of APP, but increased the phos-
phorylation of APP in a similar pattern as that of SH-SY5Y
cells overexpressing APP695. These results suggest that the
di¡erential e¡ects of p35 versus p25 on APP phosphorylation
are independent of cell type, APP isoform or the Swedish
mutation - even though the Swedish mutation at the APP
C-terminus (K670N/M671L) is in the near vicinity of the
Cdk5 phosphorylation site (Thr668). Taken together, our re-
sults demonstrate that in our cell model systems p35/Cdk5 is
able to phosphorylate both mAPP and imAPP, whereas p25/
Cdk5 is mostly pro¢cient at phosphorylating imAPP. The
mechanism(s) leading to the distinct manners of APP phos-
phorylation by p35/Cdk5 and p25/Cdk5 is unknown, but one
possibility lies in the di¡erent subcellular localization of the
two Cdk5 modulators, as well as the localization of the Cdk5
substrates ^ mAPP and imAPP. p35 contains a highly con-
served N-terminal myristoylation signal motif [19] that confers
its cell membrane distribution [15,19], which positions p35/
Cdk5 in close proximity to the transmembrane APP (both
mAPP and imAPP). On the other hand, without the N-termi-
nal membrane anchorage sequence, p25 is destined to where
the majority of the immature APP is localized.
3.2. Both p35/Cdk5 and p25/Cdk5 enhance APP processing
The signi¢cance of APPThr668 phosphorylation status has
been implicated in the regulation of APP processing.
Prompted by the observation described above that p35 and
p25 mediate APP phosphorylation distinctly, we next inves-
tigated the in£uences of p35 and p25 on APP processing. SH-
SY5Y cells constitutively expressing swAPP695 were transi-
ently transfected with either vector control or p35 or p25.
The secreted sAPPK and sAPPL proteins as well as AL pep-
Fig. 2. p35/Cdk5 and p25/Cdk5 distinctly increase APP phosphory-
lation in HEK293 cells. HEK293 constitutively expressing APP751
(A) or swAPP751 (B) were transiently transfected with the empty
vector (lane 1), the mixture of equal amounts of p35 and Cdk5
cDNA (lane 2), or the mixture of p25 and Cdk5 cDNA (lane 3).
Twenty-four hours following transfection, cells were lysed and ana-
lyzed by Western blotting. The phosphorylated mature/immature
APPThr668 and total APP were detected using the antibodies as de-
scribed above. Data are representative of three experiments.
Fig. 3. Both p35 and p25 enhance the production of AL and sAPP.
SH-SY5Y constitutively expressing swAPP695 were transfected with
empty vector, p35, or p25. Twelve hours following transfection, the
transfection mixture was replaced with fresh culture medium and
the cells were further cultured for 24 h. The conditioned media were
then collected for the measurement of AL and sAPP. A: Total AL
and AL142 in the conditioned media were quanti¢ed by ELISA as
described in Section 2. B: sAPP in the conditioned medium was de-
termined by Western immunoblotting. sAPPL was detected using an
antibody speci¢cally recognizing L-secretase-cleaved sAPP fragments
(upper blot), and sAPPK was probed with mAb 6E10 (lower blot).
Data are representative of two experiments.
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tides were detected (Fig. 3). Overexpression of p35 or p25
both signi¢cantly increased AL levels (Fig. 3A) and the secre-
tion of sAPPK/sAPPL (Fig. 3A) in the conditioned media,
suggesting that increased Cdk5 activities through p35 and
p25 overexpression indeed elevated APP processing. However,
p35 and p25 elicited similar enhancements in AL and APP
secretion i.e. p35 and p25 failed to display di¡erential e¡ects
on APP processing. The same results were obtained using
HEK293 cells constitutively expressing swAPP751 (data not
shown). These results imply that APPThr668 phosphorylation
mediated by p35/Cdk5 or p25/Cdk5 plays important roles in
the regulation of APP processing, independent of the status of
APP maturation in SH-SY5Y and HEK293.
It should be noted, however, that APP processing is rather
complex, including APP maturation, secretase cleavage and
secretion etc. Multiple kinases involved in each of the steps
could participate concomitantly in regulation of the APP pro-
cessing. For example, a recent report by Phiel et al. demon-
strated conclusively that GSK3K facilitates APP processing,
likely via regulation of secretase activity, and inhibition of the
enzyme by lithium reduces AL production [26]. Studies from
our laboratory also demonstrate a role for cAMP-dependent
protein kinase (PKA) in the regulation of APP processing
[27]. It appears that PKA-regulated APP processing is via
modulation of APP post-translational modi¢cation or matu-
ration [27]. In the present study, however, expression of p35/
Cdk5 or p25/Cdk5 did not a¡ect APP maturation although
the precise mechanism underlying the regulation of APP by
p35/Cdk5 or p25/Cdk5 is unknown.
In summary, p35 and p25 displayed di¡erential preferences
in phosphorylation of mAPP and imAPP and might render
di¡erent physiological functions of APP. p25 is known to be
elevated in AD brains and thus conceivably regulates the
preferential phosphorylation of imAPP. Although the phos-
phorylation status of imAPP or the role of imAPP in the
pathogenesis of AD awaits further investigation, our ¢ndings
provide insight into potential mechanisms that underlie the
e¡ect of p25 or activation of Cdk5 in neurons.
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